BIOTHERAPEUTIC MANUFACTURING

FOCUSING ON THE FUTURE OF BIOLOGICS MANUFACTURING

 

Business Drivers

 

More Biologic Drugs & Emergence of Biosimilars
  • Impacting Technologies
  • Greater Demands on Development
  • Higher Titers
  • Greater Efficiency
  • Higher Utilization 
Dyadic believes that the C1 technology’s high productivity provides the potential to dramatically lower biologic vaccine and drug CapEx and OpEx

When a 10,000 liter production fermenter can be reduced to a 1,000 liter production fermenter the savings are significant in at least 3 ways:

  1. Capital investment required to build launch capacity
  2. Factory with launch capacity needs to be constructed 24 month before FDA approval, or very costly CMO
  3. FDA license easier for small factorySlide 15 for Biomfg
  4. Slide 16 for Biomfg